# High Dose Flu Vaccine in Treating Children Who Have Undergone Donor Stem Cell Transplant

> **NCT02860039** · PHASE2 · COMPLETED · sponsor: **Vanderbilt-Ingram Cancer Center** · enrollment: 170 (actual)

## Conditions studied

- Hematopoietic Cell Transplantation Recipient
- Malignant Neoplasm
- Influenza

## Interventions

- **BIOLOGICAL:** Trivalent Influenza Vaccine
- **BIOLOGICAL:** Quadrivalent Influenza Vaccine
- **OTHER:** Laboratory Biomarker Analysis

## Key facts

- **NCT ID:** NCT02860039
- **Lead sponsor:** Vanderbilt-Ingram Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-09
- **Primary completion:** 2021-12-01
- **Final completion:** 2024-09
- **Target enrollment:** 170 (ACTUAL)
- **Last updated:** 2024-10-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02860039

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02860039, "High Dose Flu Vaccine in Treating Children Who Have Undergone Donor Stem Cell Transplant". Retrieved via AI Analytics 2026-08-13 from https://api.ai-analytics.org/clinical/NCT02860039. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*